George Bensch, MD
Allergy/ Immunology · Stockton, CANPI 1508839457
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,062 of the $77,832 with a category attached, or 78.5%. AstraZeneca accounts for 76.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $33,029 and has fallen 82.2% since, to $5,873 in 2025.
Across 390 payments — averaging $199.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$60K
- Boehringer Ingelheim$6K
- Pfizer$3K
- Amgen$2K
- Astrazeneca UK Limited$2K
- Octapharma USA, Inc.$777
- plus $5K from 31 others
Across 198 payments — averaging $6342.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$526K
- Teva Pharmaceuticals USA, Inc.$264K
- Sanofi US Services Inc.$204K
- Novartis$110K
- Amphastar Pharmaceuticals, Inc.$82K
- Roche Products Limited$24K
- plus $47K from 4 others
What the payments were for
- Consulting fees$3,6335%
- Speaking & faculty fees$61,06278%
- Travel & lodging$3,9285%
- Food & beverage$8,81411%
- Education$3951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 123 | $59,624 |
| Boehringer Ingelheim | 15 | $5,917 |
| Pfizer | 25 | $2,649 |
| Amgen | 15 | $2,403 |
| Astrazeneca UK Limited | 1 | $1,692 |
| Octapharma USA, Inc. | 10 | $777 |
| Regeneron Healthcare Solutions, Inc. | 10 | $556 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $537 |
| Sanofi | 27 | $530 |
| Boehringer Ingelheim International GmbH | 1 | $452 |
| Optinose US, Inc. | 16 | $383 |
| Novartis | 18 | $338 |
| CSL Behring | 11 | $172 |
| GSK | 22 | $171 |
| Biocryst US Sales Co., LLC | 8 | $170 |
| Grifols USA, LLC | 7 | $164 |
| Sanofi-aventis U.S. LLC | 2 | $155 |
| Kaleo, Inc. | 7 | $149 |
| Shire North American Group Inc | 7 | $145 |
| AbbVie | 7 | $128 |
| Pharming Healthcare, Inc. | 6 | $105 |
| Baxter Healthcare | 5 | $86 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $86 |
| Jubilant Hollisterstier LLC | 1 | $71 |
| Incyte Corporation | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Greer Laboratories, Inc. | 3 | $51 |
| Galderma Laboratories, L.p. | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Merck | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Hospira, Inc. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $16 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
| Covis Pharma GmbH | 1 | $15 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$35,799
- AIRSUPRA$12,625
- TEZSPIRE$11,108
- SYMBICORT$1,885
- EUCRISA$1,745
- BREZTRI$598
- SPIRIVA RESPIMAT$452
- DUPIXENT$248
- CUTAQUIG$238
- FARXIGA$144
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$113
- BEVESPI AEROSPHERE$110
How this compares
Too few allergy/ immunology providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 441 | $280,025 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 347 | $262,290 |
| Dupixent PenDupilumab | 49 | $183,178 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 222 | $164,591 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $141,920 |
| SymbicortBudesonide/Formoterol Fumarate | 514 | $141,834 |
| Dupixent SyringeDupilumab | 39 | $138,620 |
| XolairOmalizumab | 47 | $124,696 |
| TezspireTezepelumab-Ekko | 26 | $106,731 |
| BreynaBudesonide/Formoterol Fumarate | 342 | $67,845 |
| Breo ElliptaFluticasone/Vilanterol | 139 | $64,879 |
| DuleraMometasone/Formoterol | 165 | $59,656 |
| NucalaMepolizumab | 13 | $48,358 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 244 | $46,558 |
| Azelastine Hcl | 992 | $29,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Tezspire, Airsupra, Pulmicort Flexhaler | $59,624 | $438,467813 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $171 | $413,722595 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $5,917 | $296,006464 claims |
| Grifols USA, LLCProlastin C | $164 | $141,92011 claims |
| MerckDulera | $23 | $59,656165 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl, Proair Respiclick | $60 | $13,40746 claims |
| Optinose US, Inc.Xhance | $383 | $12,86019 claims |
| Hikma Pharmaceuticals USAEpinephrine | $25 | $6,88732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Stockton
- Gregory BenschStockton$2M
- Schuman TamSan Francisco$23K
- Cristina PorchcurrenCamarillo$19K
- Steven PragerSalinas$9K
- William CreightonBrawley$8K
- Janet Kershaw-MclennanAtascadero$8K
- Reyneiro CastroPasadena$7K
- Shouling ZhangDowney$3K
- Michael ReidSan Francisco$937
- Alan GreenGlendale$498
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.